Summary
This report shows that N-acylation of the protein kinase C (PKC) substrate Arg-Lys-Arg-Thr-Leu-Arg-Arg-Leu (RKRTLRRL) provides it with a potent inhibitory activity against PKC. N-myristoyl-RKRTLRRL inhibited Ca2+- and phosphatidylserine (PS)-dependent histone phosphorylation catalyzed by PKC with a 50% inhibitory concentration (IC50) of 5 μM, whereas neither RKRTLRRL nor myristic acid inhibited PKC-catalyzed histone phosphorylation at concentrations as high as 50 μM. A fully active, Ca2+- and PS-independent catalytic fragment of PKC can be generated by limited proteolysis. N-myristoyl-RKRTLRRL inhibited histone phosphorylation catalyzed by the catalytic fragment of PKC (IC50 = 80 μM), but neither myristic acid nor the nonmyristylated peptide inhibited the activity of the catalytic fragment at concentrations up to and including 200 μM. The Km app and Vmax app for N-myristoyl-RKRTLRRL were similar to those of RKRTLRRL. Thus, N-myristylation provided the octapeptide with an inhibitory activity against PKC but had only minor effects on its Km and Vmax app. Kinetic analysis provided evidence that the peptide inhibited PKC noncompetitively with respect to ATP. Previously, we reported that the protein kinase inhibitor H7 partially reverses Adriamycin resistance in the multidrug resistant (MDR) murine fibrosarcoma line UV-2237M-ADRR. In this report, we show that N-myristoyl-RKRTLRRL also partially reverses Adriamycin resistance in UV-2237M-ADRR cells. These results suggest that potent and selective cell permeable PKC inhibitors may be designed by N-acylating small PKC peptide substrates.
Similar content being viewed by others
References
Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 334:661–665, 1988
O'Brian CA, Ward NE: Biology of the protein kinase C family. Cancer Metastatis Rev 8:199–214, 1989
Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y: Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257:7847–7851, 1982
Arcoleo JP, Weinstein IB: Activation of protein kinase C by tumor-promoting phorbol esters, teleocidin and aplysiatoxin in the absence of added calcium. Carcinogenesis 6:213–217, 1985
Kikkawa U, Kishimoto A, Nishizuka Y: The protein kinase C family: Heterogeneity and its implications. Ann Rev Biochem 58:31–44, 1989
Housey GM, Johnson MD, Hsiao WLW, O'Brian CA, Murphy JP, Kirschmeier P, Weinstein IB: Overproduction of protein kinase C causes disordered growth control in rat fibroblasts. Cell 52:343–354, 1988
Fine RL, Patel J, Chabner BA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85:582–586, 1988
O'Brian CA, Fan D, Ward NE, Seid C, Fidler IJ: Level of protein kinase C activity correlates directly with resistance to Adriamycin in murine fibrosarcoma cells. FEBS Letts 246:78–82, 1989
Hunter T, Ling N, Cooper JA: Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature 311:480–485, 1984
DeBont HBA, Liskamp RMJ, O'Brian CA, Erkelens C, Veeneman GH, van Boom JH: Synthesis of a substrate of protein kinase C and its corresponding phosphopeptide. Intl J Peptide Protein Res 33:115–123, 1989
O'Brian CA, Ward NE, Liskamp RM, de Bont DB, van Boom JH: N-myristyl-Lys-Arg-Thr-Leu-Arg: A novel protein kinase C inhibitor. Biochem Pharmacol 39:49–57, 1990
Kripke ML, Gruys E, Fidler U: Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res 38:2962–2967, 1978
Giavazzi R, Miller L, Hart IR: Metastatic behavior of an Adriamycin-resistant murine tumor. Cancer Res 43:5081–5086, 1983
Giavazzi R, Bucana CD, Hart IR: Correlation of tumor growth inhibiting activity of macrophages exposed to Adriamycin and Adriamycin sensitivity of the target tumor cells. J Natl Cancer Inst 73:447–455, 1984
Bax A: Broad band homonuclear-decoupling in heteronuclear shift correlation NMR spectroscopy. J Magnet Resonance 53:517–520, 1983
IUPAC-IUB, Nomenclature and Symbolism for Amino Acids and Peptides. J Biol Chem 260:14, 1984
O'Brian CA, Ward NE: ATP-sensitive binding of melittin to the catalytic domain of protein kinase C. Molec Pharmacol 36:355–359, 1989
O'Brian CA, Ward NE, Anderson BW: Role of specific interactions between protein kinase C and triphenylethylenes in the inhibition of the enzyme. J Natl Cancer Inst 80:1628–1633, 1988
O'Brian CA, Ward NE: Binding of protein kinase C to N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide through its ATP binding site. Biochem Pharmacol 38:1737–1742, 1989
O'Brian CA, Lawrence DS, Kaiser ET, Weinstein IB: Protein kinase C phosphorylates the synthetic peptide Arg-Arg-Lys-Ala-Ser-Gly-Pro-Pro-Val in the presence of phospholipid plus either Ca2+ or a phorbol ester tumor promoter. Biochem Biophys Res Commun 124:296–302, 1984
Fan D, Bucana CD, O'Brian CA, Zwelling LA, Seid C, Fidler IJ: Enhancement of murine tumor cell sensitivity to Adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res 50:3619–3626, 1990
Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fune DL, Abbot BJ, Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601, 1988
O'Brian CA, Housey GM, Johnson MD, Kirschmeier P, Weinstein IB: The mechanism of action of protein kinase C: New insights through gene cloning and the study of inhibitors. Prog Cancer Res Ther 34:343–356, 1988
House C, Kemp BE: Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 238:1726–1728, 1987
Endicott JA, Eing V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58:137–171, 1989
Akiyama SI, Shiraishi N, Kuratomi Y, Nakagawa M, Kuwano M: Circumvention of multiple drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J Natl Cancer Inst 76:839–844, 1986
Ford JM, Prozialeck WC, Hait WN: Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Molec Pharmacol 35:105–115, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Brian, C.A., Ward, N.E., Liskamp, R.M. et al. A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to Adriamycin. Invest New Drugs 9, 169–179 (1991). https://doi.org/10.1007/BF00175084
Issue Date:
DOI: https://doi.org/10.1007/BF00175084